중동 및 아프리카 항응고제 치료 시장 – 2030년까지의 산업 동향 및 예측

중동 및 아프리카 항응고제 치료 시장 분석 및 규모

전 세계적으로 부정맥, 혈관 혈전색전증, 뇌졸중 및 관상동맥 질환과 같은 기타 심혈관 질환의 유병률이 빠르게 증가함에 따라 2023년에서 2030년까지의 예측 기간 동안 시장 성장이 가속화될 것으로 예상됩니다. 또한 외래 항응고제 요법의 증가, NOAC 수용 증가, 헤파린 무역 성장, 의사들 사이에서 항응고제 요법에 대한 인식 증가는 시장 성장을 더욱 완화할 것으로 추정됩니다.

Data Bridge Market Research는 2022년에 7억 4,197만 달러였던 중동 및 아프리카 항응고제 치료 시장이 2030년까지 1,292.58만 달러에 도달할 것으로 예상되며 2023-2030년 예측 기간 동안 7.7%의 CAGR을 보일 것으로 예상된다고 분석했습니다. 이는 시장 가치를 나타냅니다. "병원"은 약물에 대한 수요가 증가함에 따라 중동 및 아프리카 항응고제 치료 시장의 최종 사용자 부문을 지배합니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

중동 및 아프리카 항응고제 치료 시장 범위 및 세분화

시장 정의

항응고제 치료는 혈전 형성을 예방하고 혈관을 개방하는 데 사용되는 약물 유형입니다. 일반적으로 혈전 형성/혈전을 예방하거나 줄이는 데 도움이 되며, 뇌졸중이나 심장마비와 같은 심각한 상태의 발병 가능성을 더욱 낮춥니다.

중동 및 아프리카 항응고제 치료 시장 역학

운전자

• 심혈관 질환의 유병률 증가

 만성 혈액 질환의 사례는 기하급수적으로 증가하고 있으며 전 세계 항혈소판제 시장을 주도할 가능성이 높습니다. 심방세동, 심부정맥혈전증, 폐색전증을 포함한 심혈관 질환은 MEA 지역에서 증가하고 있습니다. 이러한 질환은 종종 혈전 형성을 방지하기 위해 항응고제 요법이 필요합니다. 심혈관 질환의 증가는 항혈소판제 시장 성장률을 주도하는 주요 요인입니다. 선진국과 개발도상국 모두에서 심혈관 질환은 사망의 주요 원인입니다.

According to the Centers for Disease Control and Prevention (CDC), over 800,000 individuals in the United States die each year from stroke and other cardiovascular disorders.

• Rising Number of Geriatric Population

Pharmaceutical companies are investing in research and development to create newer and safer anticoagulant drugs, which is expanding treatment options for patients. Expanding geriatric population worldwide is predicted to favour anticoagulation therapy demand as this population is more prone to heart diseases. The number of persons above 65 years is projected to double in the coming years. The old age people are prone to various chronic diseases such as cardiovascular diseases, which can foster the demand for anticoagulation drugs across the globe.

According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 and this number is expected 2.1 billion by 2050.

• Increasing Investment for Healthcare Infrastructure

Another significant factor influencing the growth rate of Middle East and Africa anticoagulation therapy market is the rising healthcare expenditure which helps in improving its infrastructure. Increasing disposable income in some MEA countries is making anticoagulation therapy more accessible to a broader population.

Furthermore, growing awareness among healthcare professionals and patients about the benefits of anticoagulation therapy in preventing strokes and other thrombotic events which is expected to enhance the market's growth rate.

Opportunity

• Increase in the Number of Research and Development Activities      

Pharmaceutical companies are investing in research and development to create newer and safer anticoagulant drugs, which is expanding treatment options for patients. Rising clinical trials and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Moreover, the market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Middle East and Africa anticoagulation therapy market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.

The rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the Middle East and Africa anticoagulation therapy market during the forecast period 2023-2030.

Restraint/Challenge

• High Cost Associated with the Therapy   

On the other hand, the high cost associated with the therapy are expected to obstruct the growth rate of market. The cost of anticoagulant medications, especially newer and more advanced drugs, can be a significant barrier to access for many patients in the MEA region, where healthcare affordability remains an issue will challenge the market. Moreover, the high risk of malfunctions like increased bleeding is expected to restrain and further impede the growth rate of market during the forecast period 2023-2030.

This Middle East and Africa anticoagulation therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa anticoagulation therapy market  Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In October 2019, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved Xarelto (Rivaroxaban) for the prevention of venous thromboembolism (VTE)
• In March 2019, Bristol-Myers Squibb-Pfizer Alliance announced results of Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs) in individuals with non-valvular atrial fibrillation (NVAF) and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI)

Middle East and Africa Anticoagulation Therapy Market Scope

The Middle East and Africa anticoagulation therapy market is segmented on the treatment, therapeutic class, drug type, testing devices, services, route of administration, therapeutic area, procedure, type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Arterial Thromboembolism (AT)
• Stroke
• Others

 Therapeutic Class

• Novel Oral Anticoagulants (NOAC)
• Heparin
• Vitamin K Antagonists
• Others

Drug Type

• Bivalirudin
• Dabigatran
• Edoxaban
• Betrixaban
• Rivaroxaban
• Apixaban
• Enoxaparin
• Dalteparin
• Others

Testing Devices

• In-Office Testing Devices
• Analyzers, Reagents and Kits
• Home Testing Devices

Services

• Testing Services
• Consulting

Route of Administration

• Oral
• Parenteral

Therapeutic Area

• Cardiovascular
• Respiratory
• Oncology
• Nephrology
• CNS
• Others

Procedure

• Pre-Surgical Procedures
• Post-Surgical Procedures
• Kidney Dialysis
• Heart Valve Replacement

Type

• Generics
• Branded

End User

• Hospitals
• Clinics
• Homecare
• Ambulatory Surgical Centers
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Middle East and Africa Anticoagulation Therapy Market Regional Analysis/Insights

The Middle East and Africa anticoagulation therapy market is analysed and market size insights and trends are provided by the treatment, therapeutic class, drug type, testing devices, services, route of administration, therapeutic area, procedure, type, end user and distribution channel as referenced above.

The countries covered in the Middle East and Africa anticoagulation therapy market report are Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA).

Saudi Arabia accounted the largest market share for Middle East and Africa anticoagulation therapy market due to developing healthcare sector with increasing medical devices and pharmaceutical products in the country as well as rapid rise in prevalence of arrhythmia, blood vessel thromboembolism and stroke and other cardiovascular diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Middle East and Africa anticoagulation therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Middle East and Africa anticoagulation therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Middle East and Africa anticoagulation therapy market. The data is available for historic period 2015-2020.

Competitive Landscape and Middle East and Africa Anticoagulation Therapy Market Share Analysis

중동 및 아프리카 항응고제 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 중동 및 아프리카 항응고제 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

중동 및 아프리카 항응고제 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 히크마 제약(영국)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 노바티스 AG(스위스)
• 에자이 주식회사(일본)
• 파이저 주식회사(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• Sanofi, Fresenius SE & Co. KGaA(독일)
• Fresenius Kabi AG(독일)
• Aspen Holdings(남아프리카 공화국)
• 상하이 포선제약(그룹)유한공사(중국)
• Cipla Inc(인도)
• 존슨앤존슨 프라이빗 리미티드(미국)
• Bayer AG(독일)
• 베링거인겔하임인터내셔널(독일)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 다이이치 산쿄 주식회사(일본)
• Eagle Pharmaceuticals, Inc. (미국)
• 엔도 인터내셔널 주식회사(아일랜드)
• 미쓰비시 타나베 파마 주식회사(일본)
• 타로제약산업(이스라엘)

SKU-44724